The growing need across the world to efficiently manage hemostasis and tissue sealing while performing surgery has had a great influence on the evolution of modern surgical procedures. A group of agents identified as surgical tissue adhesives has been extended to promote hemostasis and tissue sealing throughout surgery, and these comprise both natural and synthetic agents. Fibrin sealants are the most efficient tissue adhesives currently available in the market. They are biocompatible and biodegradable. The fibrin sealants are composed of refined, virus-inactivated human fibrinogen, human thrombin, and sometimes added elements, such as virus-inactivated human factor XIII and bovine aprotinin. These agents imitate the final steps of the physiological clotting cascade to create a fibrin clot. The increasing use of fibrin sealants in the healthcare industry is anticipated to fuel the global fibrin sealants market during the forecast period.
The global COVID-19 pandemic has had a significant impact on almost every industry, including the fibrin sealants market. Most of the healthcare industry shifted its focus on fighting the coronavirus outbreak, while various surgeries and diagnostic treatments were postponed, canceled, or performed in a limited amount. Surgeries performed with fibrin sealants, hemostats, or adhesion barriers have declined significantly across the world, thus hampering the growth rate of the fibrin sealants market. Businesses witnessed reduced demand for sealants with a decreasing number of surgeries. Many patients avoided operating in contagious environments fearing severe consequences. The healthcare industry suffered due to limited resources and restrictions on the global trade. Thus, it affected the growth of the fibrin sealants market.
Major market players are currently focusing on developments and innovations in the ways to conduct practices using DTC and remote operations. With the growing number of coronary artery disease across the world, the fibrin sealants market is expected to witness demand post-COVID-19. The number of these cases is anticipated to rise with the growing population and insufficient healthcare in underdeveloped countries. As the pandemic is nearing its end, companies are preparing to expand their business activities and productivity to flatten the demand curve. This might prove propitious for the global fibrin sealants market during the projected period.
Fibrin sealants are presently used in several surgical practices, including cardiovascular surgery, thoracic surgery, neurosurgery, plastic & reconstructive surgery, and dental surgery. The use of fibrin sealants has a resolute effect on surgical outcomes, such as improved time to hemostasis, decreased blood loss, and reduced complexities. The report describes the evolution of fibrin sealants, the composition of currently available products, and their use in surgical practice. Many electrosurgical instruments are available, and used for analysis and sealing vascular structures. The topical hemostatic agents, such as fibrin sealants, are used to control bleeding from surfaces or cavities that are not responsive to suturing, electrosurgery, or other functional instruments including the argon plasma coagulator. An increment in the number of surgical procedures and patients with blood-related disorders such as hemophilia is anticipated to boost the global fibrin sealants market in the upcoming future.
There is a surge in awareness about medical treatments. Combined with the rising literacy rate, there has been an increase in the adoption of new efficient surgical products, which is likely to fuel the demand in the global market. Moreover, the involvement of governments and organizations to promote information regarding chronic diseases and treatments will raise the number of patients in the upcoming future. Owing to the increasing aging population in North America, the region is expected to a hold major share of the global fibrin sealants market. The global fibrin sealants market is expected to expand at a CAGR of 6.7% from 2021 to 2031.
Analysts’ Viewpoint
The global fibrin sealant market is principally driven by the increasing predominance of important surgeries and traumatic injuries. Recent improvements in technology and products have resulted in the development of biocompatible sealants, which reduce complexities and support the normal movement of tissues without any restraint on the functioning of the organs. Furthermore, North America accounted for the highest revenue share of the fibrin sealants market in 2019 and is expected to lead the regional segment during the forecast period. Advancements in hemostasis technology and rising number of chronic diseases are likely to aid in the future growth of the fibrin sealants market.
The global fibrin sealants market was worth US$ 900 Mn and is projected to reach a value of US$ 2 Bn by the end of 2031
Fibrin sealants market is anticipated to grow at a CAGR of 6.7% during the forecast period
North America accounted for a major share of the global fibrin sealants market
Fibrin sealants market is driven by increase in number of patients with chronic diseases, rise in trauma cases, and surge in geriatric population are anticipated to drive the global market from 2021 to 2031
Key players in the global fibrin sealants market include Baxter, Pfizer, Inc., Takeda Pharmaceutical Company, Johnson & Johnson (Ethicon, Inc.), Grifols, S.A., CSL Limited, Vivostat A/S, Stryker, Hemarus, and Asahi Kasei Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fibrin Sealants Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fibrin Sealants Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events (mergers, acquisitions, collaborations, partnerships, etc.)
5.3. TISSEEL Fibrin Sealant Sales and Forecast (US$ Mn) 2017-2031, by Country/Region
5.4. % Share of Marketed Fibrin Sealants by Product/Company in the Global Fibrin Sealants Market (2020)
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Fibrin Sealants Market Analysis and Forecast, by Dosage Form
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Dosage Form, 2017–2031
6.3.1. Liquid
6.3.2. Patch
6.3.3. Powder
6.4. Market Attractiveness Analysis, by Dosage Form
7. Global Fibrin Sealants Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. General Surgery
7.3.2. Cardiovascular Surgery
7.3.3. Wound Management
7.3.4. Orthopedic Surgery
7.3.5. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Fibrin Sealants Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Fibrin Sealants Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Fibrin Sealants Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Dosage Form, 2017–2031
10.2.1. Liquid
10.2.2. Patch
10.2.3. Powder
10.3. Market Value Forecast, by Indication, 2017–2031
10.3.1. General Surgery
10.3.2. Cardiovascular Surgery
10.3.3. Wound Management
10.3.4. Orthopedic Surgery
10.3.5. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Dosage Form
10.6.2. By Indication
10.6.3. By End-user
10.6.4. By Country
11. Europe Fibrin Sealants Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Dosage Form, 2017–2031
11.2.1. Liquid
11.2.2. Patch
11.2.3. Powder
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. General Surgery
11.3.2. Cardiovascular Surgery
11.3.3. Wound Management
11.3.4. Orthopedic Surgery
11.3.5. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Dosage Form
11.6.2. By Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Fibrin Sealants Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Dosage Form, 2017–2031
12.2.1. Liquid
12.2.2. Patch
12.2.3. Powder
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. General Surgery
12.3.2. Cardiovascular Surgery
12.3.3. Wound Management
12.3.4. Orthopedic Surgery
12.3.5. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Dosage Form
12.6.2. By Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Fibrin Sealants Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Dosage Form, 2017–2031
13.2.1. Liquid
13.2.2. Patch
13.2.3. Powder
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. General Surgery
13.3.2. Cardiovascular Surgery
13.3.3. Wound Management
13.3.4. Orthopedic Surgery
13.3.5. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Dosage Form
13.6.2. By Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Fibrin Sealants Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Dosage Form, 2017–2031
14.2.1. Liquid
14.2.2. Patch
14.2.3. Powder
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. General Surgery
14.3.2. Cardiovascular Surgery
14.3.3. Wound Management
14.3.4. Orthopedic Surgery
14.3.5. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Dosage Form
14.6.2. By Indication
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2020
15.3. Company Profiles
15.3.1. Baxter
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Growth Strategies
15.3.1.3. SWOT Analysis
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Growth Strategies
15.3.2.3. SWOT Analysis
15.3.3. Takeda Pharmaceutical Company
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Growth Strategies
15.3.3.3. SWOT Analysis
15.3.4. Johnson & Johnson (Ethicon, Inc.)
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Growth Strategies
15.3.4.3. SWOT Analysis
15.3.5. Grifols, S.A.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Growth Strategies
15.3.5.3. SWOT Analysis
15.3.6. CSL Limited
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Growth Strategies
15.3.6.3. SWOT Analysis
15.3.7. Vivostat A/S
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Growth Strategies
15.3.7.3. SWOT Analysis
15.3.8. Stryker
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Growth Strategies
15.3.8.3. SWOT Analysis
15.3.9. Hemarus
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Growth Strategies
15.3.9.3. SWOT Analysis
15.3.10. Asahi Kasei Corporation
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Growth Strategies
15.3.10.3. SWOT Analysis
List of Tables
Table 01: Key Industry Events
Table 02: ISSEEL Fibrin Sealant Sales and Forecast (US$ Mn) 2017-2031, by Region
Table 03: Global Fibrin Sealant Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 04: Global Fibrin Sealant Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 05: Global Fibrin Sealant Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Fibrin Sealant Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Fibrin Sealants Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: North America Fibrin Sealants Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 09: North America Fibrin Sealants Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 10: North America Fibrin Sealants Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 11: Europe Fibrin Sealants Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Fibrin Sealants Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 13: Europe Fibrin Sealants Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 14: Europe Fibrin Sealants Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Asia Pacific Fibrin Sealants Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Asia Pacific Fibrin Sealants Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 17: Asia Pacific Fibrin Sealants Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 18: Asia Pacific Fibrin Sealants Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Latin America Fibrin Sealants Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 20: Latin America Fibrin Sealants Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 21: Latin America Fibrin Sealants Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 22: Latin America Fibrin Sealants Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 23: Middle East & Africa Fibrin Sealants Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 24: Middle East & Africa Fibrin Sealants Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 25: Middle East & Africa Fibrin Sealants Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 26: Middle East & Africa Fibrin Sealants Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Fibrin Sealant Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Fibrin Sealant Market Value Share, by Dosage Form, 2020
Figure 03: Global Fibrin Sealant Market Value Share, by Indication, 2020
Figure 04: Global Fibrin Sealant Market Value Share, by End-user, 2020
Figure 05: Global Fibrin Sealant Market Value Share, by Region, 2020
Figure 06: Global Fibrin Sealant Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 07: Global Fibrin Sealant Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 08: Global Fibrin Sealant Market Value (US$ Mn), by Liquid, 2017–2031
Figure 09: Global Fibrin Sealant Market Value (US$ Mn), by Patch, 2017–2031
Figure 10: Global Fibrin Sealant Market Value (US$ Mn), by Powder, 2017–2031
Figure 11: Global Fibrin Sealant Market Value Share Analysis, by Indication, 2020 and 2031
Figure 12: Global Fibrin Sealant Market Attractiveness Analysis, by Indication, 2021–2031
Figure 13: Global Fibrin Sealant Market Value (US$ Mn), by General Surgery, 2017–2031
Figure 14: Global Fibrin Sealant Market Value (US$ Mn), by Cardiovascular Surgery, 2017–2031
Figure 15: Global Fibrin Sealant Market Value (US$ Mn), by Wound Management, 2017–2031
Figure 16: Global Fibrin Sealant Market Value (US$ Mn), by Orthopedic Surgery, 2017–2031
Figure 17: Global Fibrin Sealant Market Value (US$ Mn), by Others, 2017–2031
Figure 18: Global Fibrin Sealant Market Value Share Analysis, by End-user, 2020 and 2031
Figure 19: Global Fibrin Sealant Market Attractiveness Analysis, by End-user, 2021–2031
Figure 20: Global Fibrin Sealant Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 21: Global Fibrin Sealant Market Value (US$ Mn), by Ambulatory Surgical Centers, 2017–2031
Figure 22: Global Fibrin Sealant Market Value (US$ Mn), by Others, 2017–2031
Figure 23: Global Fibrin Sealant Market Value Share Analysis, by Region, 2020 and 2031
Figure 24: Global Fibrin Sealant Market Attractiveness Analysis, by Region, 2021–2031
Figure 25: North America Fibrin Sealants Market Value (US$ Mn) Forecast, 2017–2031
Figure 26: North America Fibrin Sealants Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 27: North America Fibrin Sealants Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 28: North America Fibrin Sealants Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 29: North America Fibrin Sealants Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 30: North America Fibrin Sealants Market Value Share Analysis, by Indication, 2020 and 2031
Figure 31: North America Fibrin Sealants Market Attractiveness Analysis, by Indication, 2021–2031
Figure 32: North America Fibrin Sealants Market Value Share Analysis, by End-user, 2020 and 2031
Figure 33: North America Fibrin Sealants Market Attractiveness Analysis, by End-user, 2021–2031
Figure 34: Europe Fibrin Sealants Market Value (US$ Mn) Forecast, 2017–2031
Figure 35: Europe Fibrin Sealants Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 36: Europe Fibrin Sealants Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 37: Europe Fibrin Sealants Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 38: Europe Fibrin Sealants Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 39: Europe Fibrin Sealants Market Value Share Analysis, by Indication, 2020 and 2031
Figure 40: Europe Fibrin Sealants Market Attractiveness Analysis, by Indication, 2021–2031
Figure 41: Europe Fibrin Sealants Market Value Share Analysis, by End-user, 2020 and 2031
Figure 42: Europe Fibrin Sealants Market Attractiveness Analysis, by End-user, 2021–2031
Figure 43: Asia Pacific Fibrin Sealants Market Value (US$ Mn) Forecast, 2017–2031
Figure 44: Asia Pacific Fibrin Sealants Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 45: Asia Pacific Fibrin Sealants Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 46: Asia Pacific Fibrin Sealants Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 47: Asia Pacific Fibrin Sealants Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 48: Asia Pacific Fibrin Sealants Market Value Share Analysis, by Indication, 2020 and 2031
Figure 49: Asia Pacific Fibrin Sealants Market Attractiveness Analysis, by Indication, 2021–2031
Figure 50: Asia Pacific Fibrin Sealants Market Value Share Analysis, by End-user, 2020 and 2031
Figure 51: Asia Pacific Fibrin Sealants Market Attractiveness Analysis, by End-user, 2021–2031
Figure 52: Latin America Fibrin Sealants Market Value (US$ Mn) Forecast, 2017–2031
Figure 53: Latin America Fibrin Sealants Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 54: Latin America Fibrin Sealants Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 55: Latin America Fibrin Sealants Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 56: Latin America Fibrin Sealants Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 57: Latin America Fibrin Sealants Market Value Share Analysis, by Indication, 2020 and 2031
Figure 58: Latin America Fibrin Sealants Market Attractiveness Analysis, by Indication, 2021–2031
Figure 59: Latin America Fibrin Sealants Market Value Share Analysis, by End-user, 2020 and 2031
Figure 60: Latin America Fibrin Sealants Market Attractiveness Analysis, by End-user, 2021–2031
Figure 61: Middle East & Africa Fibrin Sealants Market Value (US$ Mn) Forecast, 2017–2031
Figure 62: Middle East & Africa Fibrin Sealants Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 63: Middle East & Africa Fibrin Sealants Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 64: Middle East & Africa Fibrin Sealants Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 65: Middle East & Africa Fibrin Sealants Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 66: Middle East & Africa Fibrin Sealants Market Value Share Analysis, by Indication, 2020 and 2031
Figure 67: Middle East & Africa Fibrin Sealants Market Attractiveness Analysis, by Indication, 2021–2031
Figure 68: Middle East & Africa Fibrin Sealants Market Value Share Analysis, by End-user, 2020 and 2031
Figure 69: Middle East & Africa Fibrin Sealants Market Attractiveness Analysis, by End-user, 2021–2031
Figure 70: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 – 2020
Figure 71: Baxter Breakdown of Net Sales (%), by Region/Country, 2020
Figure 72: Baxter Breakdown of Net Sales (%), by Business Units, 2020
Figure 73: Baxter R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 74: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 75: Pfizer, Inc. Breakdown of Net Sales (%) Region/Country, 2020
Figure 76: Pfizer, Inc. Breakdown of Net Sales (%), by Biopharma Segment, 2020
Figure 77: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 78: Takeda Pharmaceutical Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 79: Takeda Pharmaceutical Company Breakdown of Net Sales (%), by Region/Country, 2020
Figure 80: Takeda Pharmaceutical Company Breakdown of Net Sales (%), by Business Segment, 2020
Figure 81: Takeda Pharmaceutical Company R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 82: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 83: Johnson & Johnson Breakdown of Net Sales (%) Region/Country, 2020
Figure 84: Johnson & Johnson Breakdown of Net Sales (%), by Business Segment, 2020
Figure 85: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 86: Grifols, S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 87: Grifols, S.A. Breakdown of Net Sales (%) Region/Country, 2020
Figure 88: Grifols, S.A. Breakdown of Net Sales (%), by Business Segment, 2020
Figure 89: Grifols, S.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 90: CSL Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 91: CSL Limited Breakdown of Net Sales (%), by Region/Country, 2020
Figure 92: CSL Limited Revenue Breakdown of Net Sales (%), by Business Segment, 2020
Figure 93: CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 94: Stryker Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 95: Stryker Breakdown of Net Sales (%), by Region/Country, 2020
Figure 96: Stryker Revenue Breakdown of Net Sales (%), by Business Segment, 2020
Figure 97: Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 98: Asahi Kasei Corporation Revenue Breakdown of Net Sales (%), by Business Segment, 2019
Figure 99: Asahi Kasei Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Fibrin Sealants Market
